Eyelash trichomegaly secondary to panitumumab therapy

Current Oncology

Volumn 18, Issue 3, 2011, Pages 145-146

  Morris, L G T ^a   Hochster, H S ^b   DeLacure, M D ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidermal growth factor receptor; Eyelash; Hair; Panitumumab; Targeted therapy; Trichomegaly

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CASE REPORT; COLORECTAL CANCER; EYELASH; EYELASH TRICHOMEGALY; FEMALE; HAIR DISEASE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT;

EID: 79959312635     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i3.762     Document Type: Article

References (6)

1. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am 2008;22:1155-63.
2. Peeters M, Balfour J, Arnold D. Review article: panitumumab- a fully human anti-egfr monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 2008;28:269-81.
3. Bouché O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1711-12.
4. Melichar B, Nemcova I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 2007;16:439-43.
5. Zhang G, Basti S, Jampol L. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors. Cornea 2007;26:858-60.
6. Cancer Chemotherapy Manual. New York, NY: Wolters Kluwer; 2007: 235h-6b.